Portola Pharmaceuticals Inc. may need a randomized trial for US approval of its AndexXa (andexanet alfa) antidote for Factor Xa anticoagulants, raising concerns that this would be needed prior to approval, delaying launch by years.
Portola May Need Randomized Trial For AndexXa Approval. The Question Is When
Randomized trial represents higher bar for US approval of reversal agents for novel anticoagulants than expected – and if needed prior to approval, could delay AndexXa launch for two or maybe even four years.
More from Approval Standards
More from Pathways & Standards
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
The FDA’s accelerated approval draft guidance has left stakeholders seeking clarification of the process for determining a surrogate marker or intermediate clinical endpoint is reasonably likely to confirm clinical benefit.
• By
A risk-based approach to human cell therapies and tissue-based products could incentivize development and prevent bad actors from taking advantage of the current FDA system.